Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases

Abstract Protein aggregation is a pathological hallmark of and may play a central role in the neurotoxicity in age-associated neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. Accordingly, inhibiting aggregation of amyloidogenic proteins, including amyloid β and α-synu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoshiki Takamatsu, Gilbert Ho, Wakako Koike, Shuei Sugama, Takato Takenouchi, Masaaki Waragai, Jianshe Wei, Kazunari Sekiyama, Makoto Hashimoto
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/bc8a805344ac428e9accaa32a0c1f422
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc8a805344ac428e9accaa32a0c1f422
record_format	dspace
spelling	oai:doaj.org-article:bc8a805344ac428e9accaa32a0c1f4222021-12-02T15:10:26ZCombined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases10.1038/s41531-016-0001-12373-8057https://doaj.org/article/bc8a805344ac428e9accaa32a0c1f4222017-01-01T00:00:00Zhttps://doi.org/10.1038/s41531-016-0001-1https://doaj.org/toc/2373-8057Abstract Protein aggregation is a pathological hallmark of and may play a central role in the neurotoxicity in age-associated neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. Accordingly, inhibiting aggregation of amyloidogenic proteins, including amyloid β and α-synuclein, has been a main therapeutic target for these disorders. Among various strategies, amyloid β immunotherapy has been extensively investigated in Alzheimer’s disease, followed by similar studies of α-synuclein in Parkinson’s disease. Notably, a recent study of solanezumab, an amyloid β monoclonal antibody, raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer’s disease, but also for other neurodegenerative disorders, including Parkinson’s disease. Thus, it is expected that further refinement of immunotherapy against neurodegenerative diseases may lead to increasing efficacy. Meanwhile, type II diabetes mellitus has been associated with an increased risk of neurodegenerative disease, such as Alzheimer’s disease and Parkinson’s disease, and studies have shown that metabolic dysfunction and abnormalities surrounding insulin signaling may underlie disease progression. Naturally, “anti-insulin resistance” therapy has emerged as a novel paradigm in the therapy of neurodegenerative diseases. Indeed, incretin agonists, which stimulate pancreatic insulin secretion, reduce dopaminergic neuronal loss and suppress Parkinson’s disease disease progression in clinical trials. Similar studies are ongoing also in Alzheimer’s disease. This paper focuses on critical issues in “immunotherapy” and “anti-insulin resistance” therapy in relation to therapeutic strategies against neurodegenerative disease, and more importantly, how they might merge mechanistically at the point of suppression of protein aggregation, raising the possibility that combined immunotherapy and “anti-insulin resistance” therapy may be superior to either monotherapy.Yoshiki TakamatsuGilbert HoWakako KoikeShuei SugamaTakato TakenouchiMasaaki WaragaiJianshe WeiKazunari SekiyamaMakoto HashimotoNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 3, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Yoshiki Takamatsu Gilbert Ho Wakako Koike Shuei Sugama Takato Takenouchi Masaaki Waragai Jianshe Wei Kazunari Sekiyama Makoto Hashimoto Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
description	Abstract Protein aggregation is a pathological hallmark of and may play a central role in the neurotoxicity in age-associated neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. Accordingly, inhibiting aggregation of amyloidogenic proteins, including amyloid β and α-synuclein, has been a main therapeutic target for these disorders. Among various strategies, amyloid β immunotherapy has been extensively investigated in Alzheimer’s disease, followed by similar studies of α-synuclein in Parkinson’s disease. Notably, a recent study of solanezumab, an amyloid β monoclonal antibody, raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer’s disease, but also for other neurodegenerative disorders, including Parkinson’s disease. Thus, it is expected that further refinement of immunotherapy against neurodegenerative diseases may lead to increasing efficacy. Meanwhile, type II diabetes mellitus has been associated with an increased risk of neurodegenerative disease, such as Alzheimer’s disease and Parkinson’s disease, and studies have shown that metabolic dysfunction and abnormalities surrounding insulin signaling may underlie disease progression. Naturally, “anti-insulin resistance” therapy has emerged as a novel paradigm in the therapy of neurodegenerative diseases. Indeed, incretin agonists, which stimulate pancreatic insulin secretion, reduce dopaminergic neuronal loss and suppress Parkinson’s disease disease progression in clinical trials. Similar studies are ongoing also in Alzheimer’s disease. This paper focuses on critical issues in “immunotherapy” and “anti-insulin resistance” therapy in relation to therapeutic strategies against neurodegenerative disease, and more importantly, how they might merge mechanistically at the point of suppression of protein aggregation, raising the possibility that combined immunotherapy and “anti-insulin resistance” therapy may be superior to either monotherapy.
format	article
author	Yoshiki Takamatsu Gilbert Ho Wakako Koike Shuei Sugama Takato Takenouchi Masaaki Waragai Jianshe Wei Kazunari Sekiyama Makoto Hashimoto
author_facet	Yoshiki Takamatsu Gilbert Ho Wakako Koike Shuei Sugama Takato Takenouchi Masaaki Waragai Jianshe Wei Kazunari Sekiyama Makoto Hashimoto
author_sort	Yoshiki Takamatsu
title	Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
title_short	Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
title_full	Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
title_fullStr	Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
title_full_unstemmed	Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
title_sort	combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/bc8a805344ac428e9accaa32a0c1f422
work_keys_str_mv	AT yoshikitakamatsu combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT gilbertho combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT wakakokoike combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT shueisugama combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT takatotakenouchi combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT masaakiwaragai combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT jianshewei combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT kazunarisekiyama combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases AT makotohashimoto combinedimmunotherapywithantiinsulinresistancetherapyasanoveltherapeuticstrategyagainstneurodegenerativediseases
_version_	1718387716532469760

Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases

Ejemplares similares